MADRID (Reuters) - Barcelona have swooped to sign Brazilian forward Malcom on a five-year deal from Girondins Bordeaux for an initial 41 million euros ($47.89 million) in a surprise move after AS Roma had struck a deal with the French club. The 21-year-old was set to join the Italians this week but media reports in Spain and Italy said Spanish champions Barca’s 11th hour offer had changed Malcom’s mind and he has become their third signing of the transfer window. “This is a unique feeling, a unique feeling,” he said at Barca’s Nou Camp offices on Tuesday. “I’m delighted. It’s a dream I’ve had since childhood. I’m part of the best club in the world and I hope to give the fans a lot of joy.” In an
interview on Roma’s website here, Sporting Director Monchi explained that after the Serie A club had reached an initial agreement with Bordeaux on Monday Barcelona entered the bidding, leading Roma to submit an improved offer for the player. Bordeaux then met with Malcom’s representatives on Tuesday to discuss the transfer which is when Roma pulled out, with the club looking to see
if they have a case for legal action. “After that meeting, I was surprised to be told that the agents and Bordeaux wanted another improved offer, as Barcelona were still pushing for a deal,” Monchi said. “I told them enough, because we did not want to enter an auction: we could not continue like that, and yesterday we had only raised our offer because of the willingness and desire of our president. So that was how everything ended. “Now, within the club, we are looking at our options and seeing if we have a legal case. It is true that nothing was signed, but there are many messages with the agents and their president that are at least worth being assessed.” Media reports said Malcom’s change of destination came after Barca’s move for fellow Brazilian forward Willian broke down when they were unable to agree a transfer fee with Chelsea, leading them to turn to Bordeaux’s fleet-footed wide forward. “The Brazilian will undergo a medical on Wednesday morning and then directly join the FC Barcelona US Tour,” read a statement from the Spanish champions, whose deal for the player includes an extra one million euros in variables. Malcom joined Bordeaux from Brazilian side Corinthians in January 2016 and scored 23 goals in 96 games for the club. He is Barca’s second Brazilian signing of the transfer window after midfielder Arthur, 21, joined from Gremio. Barcelona also signed 23-year-old French defender Clement Lenglet from Sevilla earlier this month. ($1 = 0.8562 euros) for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up  Thorac Cardiovasc Surg 2015; 63(06): 510-513 Georg Thieme Verlag KG Stuttgart · New York Sandra Kampe 1 Department of Anesthesiology and Pain Medicine, Ruhrlandklinik, West German Lung Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany Gerhard Weinreich 2 Department of Pneumology,
Ruhrlandklinik, West German Lung Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany , Christopher Darr 1 Department of Anesthesiology and Pain Medicine, Ruhrlandklinik, West German Lung Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany , Georgios Stamatis 3 Department of Thoracic Surgery and Thoracic Endoscopy, Ruhrlandklinik, West German Lung Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany , Thomas Hachenberg 4 Department of Anesthesiology and Intensive Care Medicine, University Hospital of Magdeburg, Otto von Guericke University of Magdeburg, Magdeburg, Germany AbstractBackground To assess the clinical efficacy of controlled-release oxycodone for postoperative analgesia after video-assisted thoracic surgery (VATS) or thoracoscopy. Methods Pain therapy is standardized in our thoracic center throughout the complete postoperative stay. Patients receive immediately postoperative standardized oral analgesic protocol with controlled-released oxycodone (Oxy Group) or oxycodone with naloxone (Targin Group) and nonopioid every 6 h. We switched the opioid protocol from controlled-release oxycodone to Targin in January 2012. All patients are visited daily by a pain specialist throughout the whole stay. Results Data of 788 patients undergoing VATS (n = 367) or thoracoscopy (n = 421) during January 2011 until March 2013 were analyzed. In VATS, patients with Targin had higher pain scores at rest (p < 0.02) and on coughing (p < 0.001) than patients with oxycodone alone and more patients with Targin were dismissed with oral opioid dose than patients with oxycodone alone (p < 0.001). No differences in pain scores on POD 5 and 6, or in length of hospital stay, incidence of nausea, time to first dejection or opioid dose after dismission were found between controlled-release oxycodone and Targin. After conventional thoracoscopy, 209 patients received controlled-release oxycodone and 212 Targin. Patients with Targin had higher pain scores at rest (p < 0.004) and on coughing (p < 0.01) than patients with oxycodone alone and more patients with Targin were dismissed with oral opioid dose than patients with oxycodone alone (p < 0.004). There were no differences in pain scores on POD 5 and 6, or in length of hospital stay, incidence of nausea, time to first dejection or opioid dose after dismission. Conclusion Oral opioid analgesia with controlled-release oxycodone is an effective postoperative regimen after VATS and thoracoscopies. Our retrospective data indicate that Targin might be less effective analgesic than oxycodone after VATS and thoracoscopies with no improvement in bowel function in the immediate postoperative period. Study Limitations The study design is retrospective in nature. KeywordsKeywordspostoperative pain therapy - VATS - thoracoscopy - gold standard - oral opioids - length of hospital stay - recovery of bowel function
|
Was bedeuten die zahlen auf der getränkedose nose
zusammenhängende Posts
Urheberrechte © © 2024 ihoctot Inc.
